Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBIT Margin (2018 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed EBIT Margin for 10 consecutive years, with 40.52% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 379.0% year-over-year to 40.52%, compared with a TTM value of 43.77% through Dec 2025, up 409.0%, and an annual FY2025 reading of 43.77%, up 409.0% over the prior year.
  • EBIT Margin was 40.52% for Q4 2025 at Catalyst Pharmaceuticals, down from 44.66% in the prior quarter.
  • Across five years, EBIT Margin topped out at 53.79% in Q2 2022 and bottomed at 36.21% in Q3 2023.
  • Average EBIT Margin over 5 years is 37.89%, with a median of 42.63% recorded in 2021.
  • The sharpest move saw EBIT Margin crashed -8007bps in 2023, then soared 7577bps in 2024.
  • Year by year, EBIT Margin stood at 33.26% in 2021, then surged by 52bps to 50.7% in 2022, then fell by -26bps to 37.71% in 2023, then increased by 18bps to 44.31% in 2024, then decreased by -9bps to 40.52% in 2025.
  • Business Quant data shows EBIT Margin for CPRX at 40.52% in Q4 2025, 44.66% in Q3 2025, and 45.24% in Q2 2025.